Access the full text.
Sign up today, get DeepDyve free for 14 days.
V. Ovsepyan, A. Luchinin, T. Zagoskina (2014)Role of Glutathione-S-Transferase M1 (GSTM1) and T1 (GSTT1) Genes in the Development and Progress of Chronic Myeloid Leukemia and in the Formation of Response to Imatinib Therapy
Bulletin of Experimental Biology and Medicine, 158
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, A. Gratwohl, F. Guilhot, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, D. Niederwieser, R. Silver, R. Hehlmann (2006)Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Blood, 108 6
M. Baccarani, F. Castagnetti, G. Gugliotta, G. Rosti (2015)A review of the European LeukemiaNet recommendations for the management of CML
Annals of Hematology, 94
Tricia Ishimoto, F. Ali-Osman (2002)Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli.
Pharmacogenetics, 12 7
M. Baccarani, M. Deininger, G. Rosti, A. Hochhaus, S. Soverini, J. Apperley, F. Cervantes, R. Clark, J. Cortes, F. Guilhot, H. Hjorth-Hansen, T. Hughes, H. Kantarjian, Dong-Wook Kim, R. Larson, J. Lipton, F. Mahon, G. Martinelli, J. Mayer, Martin Müller, D. Niederwieser, F. Pane, J. Radich, P. Rousselot, G. Saglio, S. Saussele, C. Schiffer, R. Silver, B. Simonsson, J. Steegmann, J. Goldman, R. Hehlmann (2013)European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Blood, 122 6
M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, F. Cervantes, M. Deininger, A. Gratwohl, F. Guilhot, A. Hochhaus, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, J. Radich, B. Simonsson, R. Silver, J. Goldman, R. Hehlmann (2009)Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 35
J. Radich, M. Deininger, C. Abboud, J. Altman, E. Berman, R. Bhatia, B. Bhatnagar, P. Curtin, D. DeAngelo, J. Gotlib, G. Hobbs, M. Jagasia, H. Kantarjian, L. Maness, L. Metheny, J. Moore, A. Pallera, Philip Pancari, M. Patnaik, E. Purev, M. Rose, N. Shah, B. Smith, D. Snyder, K. Sweet, M. Talpaz, James Thompson, David Yang, K. Gregory, Hema Sundar (2018)Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN, 16 9
E. Hatem, Nadine Banna, Meng-Er Huang (2017)Multifaceted Roles of Glutathione and Glutathione-Based Systems in Carcinogenesis and Anticancer Drug Resistance.
Antioxidants & redox signaling, 27 15
J. Ge, Ai Tian, Qing-shan Wang, P. Kong, Yue Yu, Xiao-Qing Li, Xuchen Cao, Yu-mei Feng (2013)The GSTP1 105Val Allele Increases Breast Cancer Risk and Aggressiveness but Enhances Response to Cyclophosphamide Chemotherapy in North China
PLoS ONE, 8
A. Lavrov, Oksana Ustaeva, E. Adilgereeva, S. Smirnikhina, E. Chelysheva, O. Shukhov, Y. Shatokhin, S. Mordanov, A. Turkina, S. Kutsev (2017)Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia
PLoS ONE, 12
R. Siegel, K. Miller, A. Jemal (2019)Cancer statistics, 2019
CA: A Cancer Journal for Clinicians, 69
W. Al-achkar, F. Moassass, R. Aroutiounian, T. Harutyunyan, T. Liehr, A. Wafa (2017)Effect of Glutathione S-transferase mu 1 (GSTM1) gene polymorphism on chronic myeloid leukemia risk and Imatinib treatment response
Meta Gene, 12
S. Garte, L. Gaspari, A. Alexandrie, C. Ambrosone, H. Autrup, J. Autrup, H. Baranova, L. Bathum, S. Benhamou, P. Boffetta, C. Bouchardy, K. Breskvar, J. Brockmöller, I. Cascorbi, M. Clapper, C. Coutelle, A. Daly, M. Dell'omo, V. Dolžan, C. Dresler, A. Fryer, Aage Haugen, D. Hein, A. Hildesheim, A. Hirvonen, L. Hsieh, M. Ingelman-Sundberg, I. Kalina, D. Kang, M. Kihara, C. Kiyohara, P. Kremers, Phillip Lazarus, L. Marchand, M. Lechner, E. Lieshout, S. London, J. Manni, C. Maugard, S. Morita, V. Nazar‐Stewart, K. Noda, Y. Oda, F. Parl, R. Pastorelli, I. Persson, W. Peters, A. Rannug, T. Rebbeck, A. Risch, L. Roelandt, M. Romkes, D. Ryberg, J. Šalagovič, B. Schoket, J. Seidegård, P. Shields, E. Sim, D. Sinnet, Richard Strange, I. Stücker, Haruhiko Sugimura, J. To-Figueras, P. Vineis, M. Yu, E. Taioli (2001)Metabolic gene polymorphism frequencies in control populations.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 10 12
J. Higgins, S. Thompson (2002)Quantifying heterogeneity in a meta‐analysis
Statistics in Medicine, 21
Jong-Ho Park, Y. Woo, Emilia Youm, N. Hamad, H. Won, K. Naka, Eun-Ju Park, June-Hee Park, HeeKyung Kim, Sun-Hee Kim, Hyeoung-Joon Kim, Jae-Sook Ahn, S. Sohn, J. Moon, C. Jung, Silvia Park, J. Lipton, S. Kimura, Jong-Won Kim, Dennis Kim (2018)HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia
D. Moher, A. Liberati, J. Tetzlaff, D. Altman (2009)Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
PLoS Medicine, 6
Hongyan Wang, Xuehan Gao, Xiaolin Zhang, Wenjian Gong, Ziheng Peng, Bingshuang Wang, Li Wang, Saishuo Chang, Peiru Ma, Shi Wang (2018)Glutathione S-Transferase Gene Polymorphisms are Associated with an Improved Treatment Response to Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 24
R. Dersimonian, R. Dersimonian, N. Laird, N. Laird (1986)Meta-analysis in clinical trials.
Controlled clinical trials, 7 3
H. Ureshino, T. Shindo, H. Kojima, Y. Kusunoki, Y. Miyazaki, Hidenori Tanaka, H. Saji, A. Kawaguchi, S. Kimura (2018)Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML
Cancer Immunology Research, 6
A. Davies, A. Giannoudis, Jieying-Eunice Zhang, Gemma Austin, Lihui Wang, T. Holyoake, Martin Müller, L. Foroni, Panagiotis Kottaridis, M. Pirmohamed, Richard Clark (2014)Dual Glutathione‐S‐Transferase‐θ1 and ‐μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia
Clinical Pharmacology & Therapeutics, 96
A. Khrunin, A. Moisseev, V. Gorbunova, Svetlana Limborska (2010)Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients
The Pharmacogenomics Journal, 10
CC McIlwain, DM Townsend, KD Tew (2006)Glutathione S-transferase polymorphisms: cancer incidence and therapy
M. Egger, G. Smith, Martin Schneider, C. Minder (1997)Bias in meta-analysis detected by a simple, graphical test
M. Baccarani, M Dreyling, Novartis Pharma, Myers Bristol, Merck-Sharp Squibb, Wyeth-Lederle Dohme (2010)Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
Y. Kassogue, M. Quachouh, H. Dehbi, Asma Quessar, Said Benchekroun, S. Nadifi (2014)Effect of interaction of glutathione S-transferases (T1 and M1) on the hematologic and cytogenetic responses in chronic myeloid leukemia patients treated with imatinib
Medical Oncology, 31
(2018)Glutathione S-transferase gene polymorphisms are associated with an improved treatment response to cisplatin-based chemotherapy in patients with non-small cell lung cancer (NSCLC): a metaanalysis
S. Phuthong, W. Settheetham-Ishida, Sitakan Natphopsuk, T. Ishida (2018)Genetic Polymorphism of the Glutathione S-transferase Pi 1 (GSTP1) and Susceptibility to Cervical Cancer in Human Papilloma Virus Infected Northeastern Thai Women
Asian Pacific Journal of Cancer Prevention : APJCP, 19
A. Arora, E. Scholar (2005)Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Journal of Pharmacology and Experimental Therapeutics, 315
A. Demidova, L. Grinshpun (1973)[Chronic leukemias].
Fel'dsher i akusherka, 38 6
Q. Xiao, D. Deng, Hongying Li, F. Ye, Lulu Huang, Bing Zhang, Bingbing Ye, Z. Mo, Xiaobo Yang, Zhenfang Liu (2014)GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis
Annals of Hematology, 93
M. Baccarani, M. Dreyling (2008)Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 20 Suppl 4
(2002)Quantifying heterogeneity in a metaanalysis
G. Wells, G. Wells, B. Shea, B. Shea, Dianne O'Connell, J. Peterson, Welch, M. Losos, P. Tugwell, Sb Ga, G. Zello, J. Petersen (2014)The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
J. Tierney, L. Stewart, D. Ghersi, S. Burdett, M. Sydes (2007)Practical methods for incorporating summary time-to-event data into meta-analysis
Siti Makhtar, A. Husin, A. Baba, R. Ankathil (2017)Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients
Journal of Genetics, 96
N. Mantel, W. Haenszel (1959)Statistical aspects of the analysis of data from retrospective studies of disease.
Journal of the National Cancer Institute, 22 4
K. Sailaja, D. Surekha, Rao Dn, D. Rao, S. Vishnupriya (2010)Association of the GSTP1 gene (Ile105Val) polymorphism with chronic myeloid leukemia.
Asian Pacific journal of cancer prevention : APJCP, 11 2
(2019)The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri. ca/progr ams/clini cal_epide miolo gy/oxfor d.htm
D. Dixon, R. Edwards (2010)Glutathione Transferases
Golale Rostami, D. Assad, F. Ghadyani, M. Hamid, Amirhossien Karami, H. Jalaeikhoo, Ramezanali Kalahroodi (2019)Influence of glutathione S‐transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response
Molecular Genetics & Genomic Medicine, 7
J. Hayes, J. Flanagan, I. Jowsey (2005)Glutathione transferases.
Annual review of pharmacology and toxicology, 45
M. Höglund, F. Sandin, B. Simonsson (2015)Epidemiology of chronic myeloid leukaemia: an update
Annals of Hematology, 94
Xiangzhen Kong, Zihao Li, Xian Li (2016)GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis
Cancer Chemotherapy and Pharmacology, 78
P. Board, Deepthi Menon (2013)Glutathione transferases, regulators of cellular metabolism and physiology.
Biochimica et biophysica acta, 1830 5
BackgroundAlthough many earlier studies revealed an effect of glutathione-S-transferase (GST) gene polymorphisms on tyrosine kinase inhibitor (TKI) treatment responses in chronic myeloid leukemia (CML) patients, the significance of this relationship remains controversial.ObjectiveThis study aimed to review and meta-analyze treatment responses to TKIs in patients with CML and GST gene polymorphisms, including GSTT1, GSTM1, and GSTP1.Patients and MethodsWe searched four medical databases, PubMed, Web of Science, the Cochrane Library, and Embase, by using keywords related to GST gene polymorphisms and clinical responses in CML patients receiving TKI treatment. The meta-analysis was performed using RevMan version 5.3 and Comprehensive Meta-Analysis software version 3.0. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to examine the association between GSTT1, GSTM1, and GSTP1 polymorphisms and TKI treatment responses in patients with CML.ResultsThe null polymorphisms of GSTT1 and GSTM1 did not affect TKI treatment responses, while the GSTP1 Ile105Val polymorphism had a significant impact on responses to TKI. Patients who were GSTP1 variant allele carriers (AG + GG) had poor responses to TKI treatment compared to patients who were wild-type homozygote carriers (AA) (OR 1.85, 95% CI 1.31–2.62; p < 0.001).ConclusionsThis meta-analysis of patients with CML showed that G allele carriers with GSTP1 Ile105Val polymorphism had significantly worse responses to TKI treatment than wild-type homozygote carriers.
Targeted Oncology – Springer Journals
Published: Feb 23, 2020
Access the full text.
Sign up today, get DeepDyve free for 14 days.